Related references
Note: Only part of the references are listed.Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna M. E. Gustafsson et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives?
Paul H. Sugarbaker
AMERICAN JOURNAL OF SURGERY (2011)
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
Damian Wild et al.
CANCER RESEARCH (2011)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
Clinical radioimmunotherapy-the role of radiobiology
Jean-Pierre Pouget et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Jostein Dahle et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer
Mohanambe Lingappa et al.
CANCER RESEARCH (2010)
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
Todd L. Rosenblat et al.
CLINICAL CANCER RESEARCH (2010)
Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study
C. Pomel et al.
EJSO (2010)
Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies
Vincent Boudousq et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence
Wim P. Ceelen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models BY 213Bilabeled Multiple Targeted α Radioimmunoconjugates
Yong Li et al.
CLINICAL CANCER RESEARCH (2009)
Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach
Paul H. Sugarbaker
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2-A Phase I Study
Hakan Andersson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice
Birgit Pfost et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis
Lore Santoro et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model
N. Chouin et al.
RADIATION RESEARCH (2009)
Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Gabriel Glockzin et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2009)
Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb
Birgit Pfost et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
Emma Y. Song et al.
CANCER BIOLOGY & THERAPY (2008)
213Bi (α-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model
Hong Song et al.
CANCER RESEARCH (2008)
Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease
Diane E. Milenic et al.
CLINICAL CANCER RESEARCH (2008)
Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons
Jean-Pierre Pouget et al.
RADIATION RESEARCH (2008)
Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6
Michael R. Zalutsky et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats
F. Aarts et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
C. Andrew Boswell et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Biodistribution of 211At-Labeled humanized monoclonal antibody A33
Ylva Almqvist et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival
Angele L. Oei et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease
Diane E. Milenic et al.
CLINICAL CANCER RESEARCH (2007)
Fractionated radio immunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′)2:: therapeutic efficacy and myelotoxicity
Jorgen Elgqvist et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
Zhuo Zhang et al.
BLOOD (2006)
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
RH Verheijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2
DE Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Radioimmunotherapy and colorectal cancer
MJ Koppe et al.
BRITISH JOURNAL OF SURGERY (2005)
Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia
O Glehen et al.
LANCET ONCOLOGY (2004)
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes Pb-203 and Pb-212
LL Chappell et al.
NUCLEAR MEDICINE AND BIOLOGY (2000)
Share Paper
